Prosight Management’s Pliant Therapeutics PLRX Stock Holding History

Prosight Management’s Portfolio PLRX Stock Details PLRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.56M	Sell	1,370,233 -297,367	-18%	-$362K	0.27%	30
2026 Q1	$2.1M	Buy	1,667,600 +111,856	+7%	+$141K	0.34%	32
2025 Q4	$1.9M	Buy	1,555,744 +1,535,257	+7,494%	+$2.31M	0.39%	37
2025 Q3	$30.3K	Sell	20,487 -816,913	-98%	-$1.25M	0.01%	41
2025 Q2	$971K	Buy	837,400 +503,137	+151%	+$711K	0.24%	35
2025 Q1	$451K	Buy	+334,263	New	+$2.03M	0.15%	37

Other funds holding PLRX

TCM

Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return

ACM

ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $1.26B AUM 60.23% 1-Year Est. Return

LCM

Lynx1 Capital Management San Juan, Puerto Rico $866M AUM 231.68% 1-Year Est. Return

BCM

BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return

Prosight Management's PLRX Position: Q2 2026 in Review

Prosight Management reduced its Pliant Therapeutics (PLRX) stake by 18% in Q2 2026, selling an estimated $362K and leaving 1,370,233 shares worth $1.56M. The position accounts for 0.27% of the portfolio, ranked #30.

Prosight Management first reported a position in PLRX in Q1 2025 and has held it in 6 quarters since. The position peaked at $2.1M in Q1 2026. 86 funds tracked by Wall St. Rank hold PLRX as of Q2 2026.

Prosight Management held 1,370,233 shares of Pliant Therapeutics worth $1.56M as of Q2 2026.
Prosight Management sold 297,367 Pliant Therapeutics shares in Q2 2026, an estimated $362K.
Pliant Therapeutics made up 0.27% of Prosight Management's portfolio in Q2 2026, its #30 holding.
Prosight Management first reported a position in Pliant Therapeutics in Q1 2025 and has held it in 6 quarters since.
Prosight Management's Pliant Therapeutics position peaked at $2.1M in Q1 2026.
86 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q2 2026.

Based on Prosight Management's 13F filing for Q2 2026, filed 14 Aug 2026.